Search

Your search keyword '"Falda, M"' showing total 349 results
Start Over Author "Falda, M"
349 results on '"Falda, M"'

7. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT)

Author

Aoudjhane, M, Labopin, M, Gorin, N C, Shimoni, A, Ruutu, T, Kolb, H-J, Frassoni, F, Boiron, J M, Yin, J L, Finke, J, Shouten, H, Blaise, D, Falda, M, Fauser, A A, Esteve, J, Polge, E, Slavin, S, Niederwieser, D, Nagler, A, and Rocha, V

Published
2005
Full Text
View/download PDF

10. In vivo T-cell depletion with antithymocyte globulin or alemtuzumab for unrelated donor stem cell transplantation with reduced intensity conditioning: results of a multicentre randomized phase II clinical trial (the Global study) from the GITMO: O376

Author

Algarotti, A., Micò, C., Corradini, P., Falda, M., Alessandrino, E. P., Fanin, R., Tagliaferri, E., Castagna, L., Mordini, N., Sica, S., Santarone, S., Levis, A., Iori, A., Pollichieni, S., Sacchi, N., Scarano, M., Masciulli, A., Marchioli, R., Bacigalupo, A., Bosi, A., and Rambaldi, A.

Published
2013

14. Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients

Author

Rambaldi, A, Bacigalupo, A, Fanin, R, Ciceri, F, Bonifazi, F, Falda, M, Lambertenghi-Deliliers, G, Benedetti, F, Bruno, B, Corradini, P, Alessandrino, P E, Iacopino, P, Arcese, W, Scimè, R, Raimondi, R, Sica, S, Castagna, L, Lamparelli, T, Oneto, R, Lombardini, L, Pollichieni, S, Algarotti, A, Carobbio, A, Sacchi, N, and Bosi, A

Published
2012
Full Text
View/download PDF

26. Tandem auto-miniALLO approach for newly diagnosed multiple myeloma: an update of the Italian experience

Author

Bruno, B., Patriarca, F., Rotta, M., Maloney, D., Mordini, N., Casini, M., Rambaldi, A., Carnevale-Schianca, F., Allione, B., Soligo, D., Bavaro, P., Giaccone, L., Sorsasio, R., Montefusco, V., Busca, A., Fanin, R., Gallamini, A., Coser, P., Corradini, P., Levis, A., Aglietta, M., Pogliani, E., Falda, M., Massaia, M., Palumbo, A., Sandmaier, B., Storb, R., and Boccadoro, M.

Published
2005

27. Low-dose TBI-based non-myeloablative allografting in newly diagnosed multiple myeloma

Author

Bruno, B., Patriarca, F., Rotta, M., Maloney, D., Mordini, N., Casini, M., Rambaldi, A., Carnevale-Schianca, F., Allione, B., Soligo, D., Bavaro, P., De Fabritiis, P., Giaccone, L., Aitoro, G., Corradini, P., Busca, A., Fanin, R., Gallamini, A., Coser, P., Levis, A., Aglietta, M., Pogliani, E., Falda, M., Massaia, M., Palumbo, A., Sandmaier, B., Storb, R., and Boccadoro, M.

Published
2004

33. Second allogeneic HSCT in patients with acute leukaemia relapsed after a first allogeneic transplantation: a retrospective GITMO study

Author

alida dominietto, Bacigalupo, A., Bruno, B., Zecca, M., Falda, M., Di Bartolomeo, P., Arcese, W., Bosi, A., Fagioli, F., Iannitto, E., Favre, C., Rambaldi, A., Pession, A., Bandini, G., Ciceri, F., Dominietto, A, Bacigalupo, A, Bruno, B, Zecca, M, Falda, M, Di Bartolomeo, P, Arcese, W, Bosi, A, Fagioli, F, Iannitto, E, Favre, C, Rambaldi, A, Pession, A, Bandini, G, and Ciceri, Fabio

Published
2012

34. Allografting from unrelated donors in multiple myeloma: a study by the Italian bone marrow donor registry

Author

Bruno, Benedetto, Passera, R, Patriarca, F, Bonifazi, F, Montefusco, V, Falda, M, Giaccone, Luisa, Montanari, M, Bacigalupo, A, Guidi, S, Mordini, N, Rambaldi, A, Milone, G, Carella, Am, Bavaro, P, Ciceri, F, Scime, R, Benedetti, E, Levis, A, Marenco, P, Casini, M, Bosi, A, Corradini, P, Bandini, G, Fanin, R, Pollichieni, S, Boccadoro, Mario, Bruno, B, Passera, R, Patriarca, F, Bonifazi, F, Montefusco, V, Falda, M, Giaccone, L, Montanari, M, Bacigalupo, A, Guidi, S, Mordini, N, Rambaldi, A, Milone, G, Carella, Am, Bavaro, P, Ciceri, Fabio, Scime, R, Benedetti, E, Levis, A, Marenco, P, Casini, M, Bosi, A, Corradini, P, Bandini, G, Fanin, R, Pollichieni, S, and Boccadoro, M.

Published
2012

35. Limited chronic graft-versus-host disease is associated with better survival after alternative donor transplants for haematological malignancies: a retrospective GITMO analysis

Author

Crocchiolo, R., Ciceri, F., Teresa Lamparelli, Oneto, R., Bruno, B., Sormani, M. P., Fanin, R., Bandini, G., Bosi, A., Rambaldi, A., Alessandrino, E., Falda, M., Bacigalupo, A., Crocchiolo, R, Ciceri, Fabio, Lamparelli, T, Oneto, R, Bruno, B, Sormani, Mp, Fanin, R, Bandini, G, Bosi, A, Rambaldi, A, Alessandrino, E, Falda, M, and Bacigalupo, A.

Published
2010

37. Treatment of refractory chronic GVHD with rituximab: a GITMO study

Author

ZAJA, Francesco, BACIGALUPO A, PATRIARCA, Francesca, STANZANI M, VAN LINT M. T, FILÌ C, SCIME R, MILONE G, FALDA M, VENER C, LASZLO D, ALESSANDRINO P. E, NARNI F, SICA S, OLIVIERI A, SPEROTTO A, BOSI A, BONIFAZI F, FANIN, Renato, GITMO GRUPPO ITALIANO TRAPIANTO MIDOLLO OSSEO, Zaja, Francesco, Bacigalupo, A, Patriarca, Francesca, Stanzani, M, VAN LINT M., T, Filì, C, Scime, R, Milone, G, Falda, M, Vener, C, Laszlo, D, ALESSANDRINO P., E, Narni, F, Sica, S, Olivieri, A, Sperotto, A, Bosi, A, Bonifazi, F, Fanin, Renato, and GITMO GRUPPO ITALIANO TRAPIANTO MIDOLLO, Osseo

Abstract

The anti-CD20 chimaeric monoclonal antibody Rituximab has recently been shown to induce significant clinical response in a proportion of patients with refractory chronic graft-versus-host disease (cGVHD). We now report 38 patients, median age 48 years (22-61), receiving Rituximab for refractory cGVHD, assessed for clinical response and survival. Median duration of cGVHD before Rituximab was 23 months (range 2-116), the median number of failed treatment lines was 3 (range 1 to > or =6) and the median follow-up after Rituximab was 11 months (1-88). Overall response rate was 65%: skin 17/20 (63%), mouth 10/21 (48%), eyes 6/14 (43%), liver 3/12 (25%), lung 3/8 (37.5%), joints 4/5, gut 3/4, thrombocytopaenia 2/3, vagina 0/2, pure red cell aplasia 0/1 and, myasthenia gravis 1/1. During the study period 8/38 died: causes of death were cGVHD progression (n=3), disease relapse (n=1), infection (n=3), sudden death (n=1). The actuarial 2 year survival is currently 76%. We confirm that Rituximab is effective in over 50% of patients with refractory cGVHD and may have a beneficial impact on survival.

Published
2007

38. Retrospective comparison of transplant from matched unrelated donor or identical sibling in adult MDS: evidence for a graft-versus-myelodysplasia effect in unrelated donor transplant

Author

Alessandrino E, Bacigalupo A, Falda M, Deliliers GL, Arcese W, Benedetti F, Di Bartolomeo P, La Nasa G, Rambaldi A, Pioltelli P, De Fabritiis P, Marenco P, Pascutto C, Bandini G, Fanin R, Bosi A., CICERI , FABIO, Alessandrino, E, Bacigalupo, A, Falda, M, Deliliers, Gl, Arcese, W, Benedetti, F, Ciceri, Fabio, Di Bartolomeo, P, La Nasa, G, Rambaldi, A, Pioltelli, P, De Fabritiis, P, Marenco, P, Pascutto, C, Bandini, G, Fanin, R, and Bosi, A.

Published
2007

39. An expanded evaluation of protein function prediction methods shows an improvement in accuracy

Author

Jiang, Y, Oron, TR, Clark, WT, Bankapur, AR, D'Andrea, D, Lepore, R, Funk, CS, Kahanda, I, Verspoor, KM, Ben-Hur, A, Koo, DCE, Penfold-Brown, D, Shasha, D, Youngs, N, Bonneau, R, Lin, A, Sahraeian, SME, Martelli, PL, Profiti, G, Casadio, R, Cao, R, Zhong, Z, Cheng, J, Altenhoff, A, Skunca, N, Dessimoz, C, Dogan, T, Hakala, K, Kaewphan, S, Mehryary, F, Salakoski, T, Ginter, F, Fang, H, Smithers, B, Oates, M, Gough, J, Toronen, P, Koskinen, P, Holm, L, Chen, C-T, Hsu, W-L, Bryson, K, Cozzetto, D, Minneci, F, Jones, DT, Chapman, S, Dukka, BKC, Khan, IK, Kihara, D, Ofer, D, Rappoport, N, Stern, A, Cibrian-Uhalte, E, Denny, P, Foulger, RE, Hieta, R, Legge, D, Lovering, RC, Magrane, M, Melidoni, AN, Mutowo-Meullenet, P, Pichler, K, Shypitsyna, A, Li, B, Zakeri, P, ElShal, S, Tranchevent, L-C, Das, S, Dawson, NL, Lee, D, Lees, JG, Sillitoe, I, Bhat, P, Nepusz, T, Romero, AE, Sasidharan, R, Yang, H, Paccanaro, A, Gillis, J, Sedeno-Cortes, AE, Pavlidis, P, Feng, S, Cejuela, JM, Goldberg, T, Hamp, T, Richter, L, Salamov, A, Gabaldon, T, Marcet-Houben, M, Supek, F, Gong, Q, Ning, W, Zhou, Y, Tian, W, Falda, M, Fontana, P, Lavezzo, E, Toppo, S, Ferrari, C, Giollo, M, Piovesan, D, Tosatto, SCE, del Pozo, A, Fernandez, JM, Maietta, P, Valencia, A, Tress, ML, Benso, A, Di Carlo, S, Politano, G, Savino, A, Rehman, HU, Re, M, Mesiti, M, Valentini, G, Bargsten, JW, van Dijk, ADJ, Gemovic, B, Glisic, S, Perovic, V, Veljkovic, V, Veljkovic, N, Almeida-e-Silva, DC, Vencio, RZN, Sharan, M, Vogel, J, Kansakar, L, Zhang, S, Vucetic, S, Wang, Z, Sternberg, MJE, Wass, MN, Huntley, RP, Martin, MJ, O'Donovan, C, Robinson, PN, Moreau, Y, Tramontano, A, Babbitt, PC, Brenner, SE, Linial, M, Orengo, CA, Rost, B, Greene, CS, Mooney, SD, Friedberg, I, Radivojac, P, Jiang, Y, Oron, TR, Clark, WT, Bankapur, AR, D'Andrea, D, Lepore, R, Funk, CS, Kahanda, I, Verspoor, KM, Ben-Hur, A, Koo, DCE, Penfold-Brown, D, Shasha, D, Youngs, N, Bonneau, R, Lin, A, Sahraeian, SME, Martelli, PL, Profiti, G, Casadio, R, Cao, R, Zhong, Z, Cheng, J, Altenhoff, A, Skunca, N, Dessimoz, C, Dogan, T, Hakala, K, Kaewphan, S, Mehryary, F, Salakoski, T, Ginter, F, Fang, H, Smithers, B, Oates, M, Gough, J, Toronen, P, Koskinen, P, Holm, L, Chen, C-T, Hsu, W-L, Bryson, K, Cozzetto, D, Minneci, F, Jones, DT, Chapman, S, Dukka, BKC, Khan, IK, Kihara, D, Ofer, D, Rappoport, N, Stern, A, Cibrian-Uhalte, E, Denny, P, Foulger, RE, Hieta, R, Legge, D, Lovering, RC, Magrane, M, Melidoni, AN, Mutowo-Meullenet, P, Pichler, K, Shypitsyna, A, Li, B, Zakeri, P, ElShal, S, Tranchevent, L-C, Das, S, Dawson, NL, Lee, D, Lees, JG, Sillitoe, I, Bhat, P, Nepusz, T, Romero, AE, Sasidharan, R, Yang, H, Paccanaro, A, Gillis, J, Sedeno-Cortes, AE, Pavlidis, P, Feng, S, Cejuela, JM, Goldberg, T, Hamp, T, Richter, L, Salamov, A, Gabaldon, T, Marcet-Houben, M, Supek, F, Gong, Q, Ning, W, Zhou, Y, Tian, W, Falda, M, Fontana, P, Lavezzo, E, Toppo, S, Ferrari, C, Giollo, M, Piovesan, D, Tosatto, SCE, del Pozo, A, Fernandez, JM, Maietta, P, Valencia, A, Tress, ML, Benso, A, Di Carlo, S, Politano, G, Savino, A, Rehman, HU, Re, M, Mesiti, M, Valentini, G, Bargsten, JW, van Dijk, ADJ, Gemovic, B, Glisic, S, Perovic, V, Veljkovic, V, Veljkovic, N, Almeida-e-Silva, DC, Vencio, RZN, Sharan, M, Vogel, J, Kansakar, L, Zhang, S, Vucetic, S, Wang, Z, Sternberg, MJE, Wass, MN, Huntley, RP, Martin, MJ, O'Donovan, C, Robinson, PN, Moreau, Y, Tramontano, A, Babbitt, PC, Brenner, SE, Linial, M, Orengo, CA, Rost, B, Greene, CS, Mooney, SD, Friedberg, I, and Radivojac, P

Abstract

BACKGROUND: A major bottleneck in our understanding of the molecular underpinnings of life is the assignment of function to proteins. While molecular experiments provide the most reliable annotation of proteins, their relatively low throughput and restricted purview have led to an increasing role for computational function prediction. However, assessing methods for protein function prediction and tracking progress in the field remain challenging. RESULTS: We conducted the second critical assessment of functional annotation (CAFA), a timed challenge to assess computational methods that automatically assign protein function. We evaluated 126 methods from 56 research groups for their ability to predict biological functions using Gene Ontology and gene-disease associations using Human Phenotype Ontology on a set of 3681 proteins from 18 species. CAFA2 featured expanded analysis compared with CAFA1, with regards to data set size, variety, and assessment metrics. To review progress in the field, the analysis compared the best methods from CAFA1 to those of CAFA2. CONCLUSIONS: The top-performing methods in CAFA2 outperformed those from CAFA1. This increased accuracy can be attributed to a combination of the growing number of experimental annotations and improved methods for function prediction. The assessment also revealed that the definition of top-performing algorithms is ontology specific, that different performance metrics can be used to probe the nature of accurate predictions, and the relative diversity of predictions in the biological process and human phenotype ontologies. While there was methodological improvement between CAFA1 and CAFA2, the interpretation of results and usefulness of individual methods remain context-dependent.

Published
2016

40. Reduced-intensity conditioning followed by allografting in patients with advanced haematological malignancies older than 60 years

Author

Olivieri A, Lucesole M, Cecchi S, Dodero A, Bregni M, Tarella C, Falda M, Locasciulli A, Scime R, Patriarca F, Casini M, Bacigalupo A, Corradini P., CICERI , FABIO, Olivieri, A, Lucesole, M, Cecchi, S, Dodero, A, Ciceri, Fabio, Bregni, M, Tarella, C, Falda, M, Locasciulli, A, Scime, R, Patriarca, F, Casini, M, Bacigalupo, A, and Corradini, P.

Published
2004

43. Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome

Author

Alessandrino, Ep, Porta, Mg, Malcovati, L, Jackson, Ch, Pascutto, C, Bacigalupo, A, Teresa van Lint, M, Falda, M, Bernardi, M, Onida, F, Guidi, S, Iori, Ap, Cerretti, R, Marenco, P, Pioltelli, P, Angelucci, E, Oneto, R, Ripamonti, F, Rambaldi, A, Bosi, A, Cazzola, M, Gruppo Italiano Trapianto di Midollo Osseo Levis, A, Bandini, G, Casini, M, Rossi, G, Baronciani, D, La Nasa, G, Milone, G, Mordini, N, Van Lint MT, Corradini, P, Milani, R, Morra, E, Lambertenghi Deliliers, G, Ciceri, F, Castagna, L, Narni, F, Selleri, C, Scime, R, Iannitto, E, Musso, M, Locatelli, F, Zecca, M, Martelli, F, Visani, G, Di Bartolomeo, P, Cavanna, L, Papineschi, Federico, Messina, G, Merli, F, Foa, R, Locasciulli, A, Majolino, I, Chiusolo, P, Leone, G, Arcese, W, Carella, Am, Cascavilla, N, Mazza, P, Bruno, B, Boccadoro, M, Fanin, R, Cerno, M, Bortolo, S, and Author information, Raimondi R.

Subjects
Oncology, Adolescent, Adult, Aged, Aged, 80 and over, Child, Cohort Studies, Female, Humans, Male, Markov Chains, Middle Aged, Myelodysplastic Syndromes, Risk, Survival Analysis, Time Factors, Transplantation, Homologous, Hematopoietic Stem Cell Transplantation, Hematology, Homologous, medicine.medical_specialty, Allogeneic transplantation, medicine.medical_treatment, Hematopoietic stem cell transplantation, Natural history of disease, Internal medicine, medicine, 80 and over, Survival analysis, Transplantation, business.industry, Myelodysplastic syndromes, Original Articles, medicine.disease, Settore MED/15, Surgery, allogeneic transplantation, International Prognostic Scoring System, Risk assessment, business
Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) represents the only curative treatment for patients with myelodysplastic syndrome (MDS), but involves non-negligible morbidity and mortality. Registry studies have shown that advanced disease stage at transplantation is associated with inferior overall survival. To define the optimal timing of allogeneic HSCT, we carried out a decision analysis by studying 660 patients who received best supportive care and 449 subjects who underwent transplantation. Risk assessment was based on both the International Prognostic Scoring System (IPSS) and the World Health Organization classification-based Prognostic Scoring System (WPSS). We used a continuous-time multistate Markov model to describe the natural history of disease and evaluate the effect of allogeneic HSCT on survival. This model estimated life expectancy from diagnosis according to treatment policy at different risk stages. Relative to supportive care, estimated life expectancy increased when transplantation was delayed from the initial stages until progression to intermediate-1 IPSS-risk or to intermediate WPSS-risk stage, and then decreased for higher risks. Modeling decision analysis on WPSS versus IPSS allowed better estimation of the optimal timing of transplantation. These observations indicate that allogeneic HSCT offers optimal survival benefits when the procedure is performed before MDS patients progress to advanced disease stages. Am. J. Hematol. 88:581–588, 2013. © 2013 Wiley Periodicals, Inc.

Published
2013

44. Reduced intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in leukemias and lymphomas

Author

Corradini P, Tarella C, Olivieri A, Gianni AM, Voena C, Zallio F, Ladetto M, Falda M, Moira L, Dodero A, Rambaldi A, Sajeva MR, Tresoldi MIO, Bregni M., CICERI , FABIO, BORDIGNON, CLAUDIO, Corradini, P, Tarella, C, Olivieri, A, Gianni, Am, Voena, C, Zallio, F, Ladetto, M, Falda, M, Moira, L, Dodero, A, Ciceri, Fabio, Rambaldi, A, Sajeva, Mr, Tresoldi, Mio, Bordignon, Claudio, and Bregni, M.

Published
2001

47. Blood stream infections after allogeneic stem cell transplantation: a single-center experience with the use of levofloxacin prophylaxis

Author

Busca, A., Cavecchia, I., Locatelli, F., D'Ardia, S., DE ROSA, Francesco Giuseppe, Marmont, F., Ciccone, G., Baldi, I., Serra, R., Gaido, E., and Falda, M.

Subjects
Adult, Male, Ofloxacin, Adolescent, Incidence, Hematopoietic Stem Cell Transplantation, Candidemia, Bacteremia, Levofloxacin, Antibiotic Prophylaxis, Middle Aged, Gram-Positive Bacteria, Anti-Bacterial Agents, Young Adult, Candida albicans, Drug Resistance, Bacterial, Gram-Negative Bacteria, Humans, Transplantation, Homologous, Female, Aged, Candida, Fluoroquinolones
Abstract

Blood stream infections (BSIs) remain one of the major causes of morbidity and mortality for patients receiving an allogeneic hematopoietic stem cell transplantation (HSCT). In the present study, we evaluated the incidence and characteristics of BSI within 1 year after allogeneic HSCT in 269 consecutive adult patients who received antibacterial prophylaxis with levofloxacin. Cumulative incidence of BSI was 12% (95% confidence interval, 8-16%). Bacteria were responsible for 30 out of the 32 BSI, while fungi were responsible for 2 episodes of BSI. The median onset of BSI was day 8 (range 1-328 days) post transplant, and 66% of BSI occurred before neutrophil recovery. Gram-positive organisms accounted for 60% (n=18) of bacteremia, and gram-negative isolates for 40% (n=12) of the cases. Coagulase-negative staphylococci were the most commonly isolated gram-positive pathogens (53% of the cases), while Escherichia coli was the most commonly isolated gram-negative bacteria (58% of the cases). Candida albicans and Candida guillermondii were isolated from patients with candidemia. Resistance to fluoroquinolones (FQ) was common with 13% of gram-positive isolates being susceptible to FQ, while 50% of the gram-negative rods were susceptible to FQ. Crude mortality and mortality attributable to BSI were both 3% (1 of 32). In conclusion, our data suggest that despite the emergence of antibiotic resistance, FQ prophylaxis may be considered an appealing approach in allogeneic HSCT recipients and is also worth evaluating in randomized studies.

Published
2011

48. Allogeneic transplantation improves the overall and progression free-survival of Hodgkin's lymphoma patients relapsing after autologuos transplantation: a GITMO retrospective study based on time of HLA typing and donor availability

Author

Sarina, B, Castagna, L, Farina, F, Patriarca, F, Benedetti, Fabio, Carella, Am, Falda, M, Guidi, S, Ciceri, F, Bonini, A, Ferrari, S, Malagola, M, Morello, E, Milone, G, Bruno, B, Mordini, N, Viviani, S, Levis, A, Giordano, L, Santoro, A, and Corradini, P.

Subjects
ALLOGENEIC BONE MARROW, TRANSPLANT, RELAPSE
Published
2010

Catalog

Books, media, physical & digital resources
See catalog results